Gland Pharma to hold 47th AGM on August 28, 2025; Board recommends ₹18 dividend for FY25
The announcement details the agenda for the 47th AGM, including the recommendation of a dividend, re-appointment of directors, and appointment of secretarial auditors, which are important governance and financial events for the company and its shareholders.
The announcement includes the recommendation of a final dividend of ₹18 per equity share for the financial year ended March 31, 2025, which is a positive development for shareholders.
* Gland Pharma Limited will hold its 47th Annual General Meeting (AGM) on Thursday, August 28, 2025, at 11:00 A.M (IST). * The meeting will be conducted through Video Conference/Other Audio-Visual Means (VC/OAVM). * Key agenda items for the AGM include: * Adoption of audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2025. * Declaration of a final dividend of ₹18 per equity share of face value ₹1 for the financial year ended March 31, 2025. The record date for eligible shareholders is Thursday, August 14, 2025. * Re-appointment of Dr. Jia Ai Zhang and Mr. Srinivas Sadu as Directors. * Approval for the appointment of M/s. RVR & Associates as Secretarial Auditors for a term of five consecutive years. * Re-appointment of Mr. Essaji Goolam Vahanvati as an Independent Director for a second term of five years (September 30, 2025, to September 29, 2030), with a proposed commission of 0.1% on audited net profits, capped at ₹25 lakh (₹2,500,000) per annum. * E-voting details are provided: voting starts on Monday, August 25, 2025, at 9:00 A.M (IST) and ends on Wednesday, August 27, 2025, at 5:00 P.M (IST). The cut-off date for e-voting is Thursday, August 21, 2025. * The Notice of AGM and Annual Report for FY 2024-25 are available on the company's website and will be sent electronically to registered members.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under agm-egm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.